New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
07:33 EDTOPXA, MKGAYOpexa Therapeutics, Merck Serono enter into license agreement for Tcelna
Opexa Therapeutics (OPXA) announced the execution of an agreement with Merck Serono, a division of Merck (MKGAY) for the development and commercialization of Tcelna, a potential first-in-class personalized T-cell therapy for patients suffering from multiple sclerosis. Tcelna is being developed by Opexa and currently is in a Phase IIb clinical trial in patients with Secondary Progressive MS. Potential payments to Opexa from the option and license agreement could total $225M based upon the successful development and commercialization of Tcelna for MS. Under the terms of the agreement, Opexa will receive an upfront payment of $5M for granting an option to Merck Serono for the exclusive license of the Tcelna program for the treatment of MS. The option may be exercised prior to or upon completion of Opexa’s ongoing Phase IIb clinical trial in patients with SPMS. Upon exercising this licensing option, Merck Serono would pay an upfront license fee of either $25M or $15M, and in return receive worldwide development and commercial rights to Tcelna in MS, excluding Japan. Additional financial considerations of the agreement include development and commercial milestone payments to Opexa of up to $195M and a tiered royalty rate from the high single digits to the mid-teens based on net sales payable to Opexa.
News For OPXA;MKGAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
07:01 EDTOPXAOpexa granted new T-cell patents covering Tcelna
Opexa announced the issuance of four additional key patents covering its broad T-cell immunotherapy platform. The recent allowances bring the number of granted U.S. and international patents in Opexa's patent portfolio to 160, including in-licensed patents. The expansion of Opexa's intellectual property portfolio further strengthens the patent estate surrounding Tcelna, Opexa's personalized T-cell immunotherapy in development for the treatment of secondary progressive multiple sclerosis. Recently-granted European Patent Nos. 1546719, 2016414 and 2420833 are directed to Opexa's proprietary methods for preparing individualized T-cell vaccines, while European Patent No. 2363710 is directed to the autologous T-cell vaccine compositions themselves. The claims cover the use of particular immunodominant epitopes found in myelin basic protein, proteolipid protein and myelin oligodendrocyte protein in the preparation of such T-cell vaccines, as well as the identification and use of specific antigenic epitopes that are disease-relevant for individual patients from these and other polypeptide antigens.
October 1, 2015
05:41 EDTMKGAYBioMarin to acquire rights to Phenylketonuria franchise from Merck Serono
Subscribe for More Information
September 28, 2015
07:02 EDTMKGAYSigma-Aldrich and Merck GaA 'making progress' toward completing acquisition
Sigma-Aldrich (SIAL) announced it is making progress toward closing the planned acquisition of the Company by Merck KGaA (MKGAY), Darmstadt, Germany. The closing is now expected within the next two months. On August 11, 2015, Sigma-Aldrich and Merck announced they had obtained all necessary antitrust approvals, with the approval of the European Commission (EC) being conditional upon the sale of parts of Sigma-Aldrich's solvents and inorganics business in Europe. Negotiations with potential buyers are in the final stage. Once a binding agreement has been signed, the EC must approve the buyer before Merck can complete the Sigma-Aldrich acquisition. On September 22, 2014, Merck and Sigma-Aldrich announced they had entered into a definitive agreement under which Merck, will acquire Sigma-Aldrich for $17 billion - $140 cash per share, establishing one of the leading players in the $130 billion global life science industry.
07:01 EDTOPXAOpexa Therapeutics announces 1-for-8 reverse stock split
Subscribe for More Information
September 25, 2015
07:03 EDTMKGAYMerck KGaA, Pfizer announce FDA orphan drug designation for avelumab
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use